Investment Thesis
Anixa Biosciences is a pre-revenue pharmaceutical company burning cash at an unsustainable rate with minimal revenue generation ($210K), negative operating margins exceeding -1200%, and persistent operating losses. Despite strong balance sheet liquidity, the company is consuming capital rapidly with no clear path to profitability, making it a high-risk speculative entity dependent on successful drug development and future financing.
Strengths
- Strong current ratio of 12.18x indicates adequate short-term liquidity to fund operations
- Low debt-to-equity ratio of 0.02x provides minimal financial leverage risk
- Substantial stockholders' equity of $15.1M provides some capital cushion for R&D investments
Risks
- Severe cash burn with negative operating cash flow of -$2.6M while generating only $210K in revenue
- Extreme negative profitability margins (-1293% operating margin, -1221% net margin) indicating substantial losses relative to minimal revenue
- High dependency on future financing and successful clinical trial outcomes with no demonstrated ability to generate sustainable revenue
- Cash runway limited to approximately 7 months at current burn rate if no additional capital is raised
Key Metrics to Watch
- Quarterly operating cash flow trend and runway duration
- Revenue growth trajectory from pipeline programs and partnerships
- Clinical trial progress and regulatory milestones for lead drug candidates
- Changes in cash balance and capital raising activities
- Operating expense management and R&D spending efficiency
Financial Metrics
Revenue
210.0K
Net Income
-2.6M
EPS (Diluted)
$-0.08
Free Cash Flow
-2.6M
Total Assets
15.2M
Cash
1.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,293.3%
Net Margin
-1,221.4%
ROE
-17.0%
ROA
-16.8%
FCF Margin
-1,250.4%
Balance Sheet & Liquidity
Current Ratio
12.18x
Quick Ratio
12.18x
Debt/Equity
0.02x
Debt/Assets
9.1%
Interest Coverage
-83.04x
Long-term Debt
370.2K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T18:15:21.022464 |
Data as of: 2026-01-31 |
Powered by Claude AI